- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07506863
En undersøgelse af effekt, farmakokinetik og sikkerhed ved mitapivat hos børn med transfusionsafhængig alfa- eller beta-thalassemi (α- eller β-TDT) (ENERGIZEKids-T)
En fase 3, dobbeltblind, randomiseret, placebokontrolleret, multicenterundersøgelse, der evaluerer effektiviteten, farmakokinetikken og sikkerheden af Mitapivat hos børn med α- eller β-transfusionsafhængig thalassæmi
The primary objective of this study is to compare the effect of mitapivat versus placebo on transfusion burden in pediatric participants with α- or β-transfusion-dependent thalassemia.
Studieoversigt
Status
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
- Navn: Agios Medical Affairs
- Telefonnummer: 833-228-8474
- E-mail: medinfo@agios.com
Studiesteder
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30322
- Rekruttering
- Emory-Children's Center/ Children's Healthcare of Atlanta: Arthur M. Blank Hospital
-
-
New York
-
New York, New York, Forenede Stater, 10065
- Rekruttering
- Weill Cornell Medical College/ New York Presbyterian
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104-4318
- Rekruttering
- Children's Hospital of Philadelphia
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75390
- Rekruttering
- University of Texas Southwestern Medical Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Written informed consent/assent from the participant (or their legally authorized representative, parent(s), or legal guardian) must be obtained before any study-related procedures are conducted and participants must be willing to comply with all study procedures for the duration of the study.
- Aged 1 to <18 years and weighing at least 7 kilograms (kg) at the time of providing informed consent/assent.
- Documented diagnosis of thalassemia (β-thalassemia with or without α-globin gene mutations, hemoglobin E (HbE)/β-thalassemia, or α-thalassemia/hemoglobin H (HbH) disease) based on Hemoglobin (Hb) electrophoresis, Hb high-performance liquid chromatography, and/or DNA analysis from the participant's medical record. If this information is not available from the participant's medical record, the test(s) can be performed by a local laboratory during the Screening Period. If a local laboratory is unable to perform the test(s), results from the comprehensive α- and β-globin genotyping performed by the study central laboratory can be used.
- Transfusion dependent, defined as 6 to 20 transfusion episodes (also referred to as "transfusion events") and a ≤6-week transfusion-free period during the 24-week period before randomization.
- If taking hydroxyurea, the hydroxyurea dose must be stable for ≥16 weeks before randomization.
- Female participants who have attained menarche must be abstinent of sexual activities that may induce pregnancy as part of their usual lifestyle, or agree to use 2 forms of contraception, 1 of which must be considered highly effective, from the time of informed consent/assent, throughout the study, and for 28 days after the last dose of study drug. The second form of contraception can include an acceptable barrier method.
Exclusion Criteria:
-
Pregnant or breastfeeding.
-
Documented history of homozygous or heterozygous hemoglobin S (HbS) or hemoglobin C (HbC).
-
Prior exposure to gene therapy or prior bone marrow or stem cell transplantation, including any prior exposure to myeloablative chemotherapy.
-
Any conditions other than thalassemia expected to affect sexual maturation.
-
Currently receiving treatment with luspatercept; the last dose must have been administered ≥36 weeks before randomization.
-
Currently receiving treatment with hematopoietic stimulating agents; the last dose must have been administered ≥36 weeks before randomization.
-
History of malignancy (active or treated) ≤5 years before providing informed consent/assent, except for nonmelanomatous skin cancer in situ, cervical carcinoma in situ, or breast carcinoma in situ.
-
History of active and/or uncontrolled cardiac or pulmonary disease or clinically relevant QT prolongation within 6 months before providing informed consent/assent.
-
Hepatobiliary disorders, including but not limited to:
- Liver disease with histopathological evidence or clinical diagnosis of cirrhosis or severe fibrosis.
- Clinically symptomatic cholelithiasis or cholecystitis (prior cholecystectomy is not exclusionary).
- History of drug-induced cholestatic hepatitis.
- Aspartate Aminotransferase (AST) >2.5*Upper Limit of Normal (ULN) (unless due to hemolysis and hepatic iron deposition) and Alanine Transaminase (ALT) >2.5*ULN (unless due to hepatic iron deposition).
-
Renal dysfunction as defined by an estimated glomerular filtration rate <60 milliliters per minute (mL/min)/1.73-meter square (m^2).
-
Nonfasting triglycerides >215 milligrams per deciliter (mg/dL) [5 millimole per liter (mmol/L)].
-
Active infection requiring systemic antimicrobial therapy at the time of providing informed consent/assent. If antimicrobial therapy is required during the Screening Period, screening procedures should not be performed while antimicrobial therapy is being administered, and the last dose of antimicrobial therapy must be administered ≥7 days before randomization.
-
Participants with known active hepatitis B or hepatitis C virus infection.
-
Participants with known human immunodeficiency virus (HIV) infection.
-
History of major surgery (including splenectomy) ≤ 6 months before providing informed consent/assent and/or a major surgical procedure planned during the study.
-
Current enrollment or past participation (within ≤12 weeks or a timeframe equivalent to 5 half-lives of the investigational study drug before administration of the first dose of study drug, whichever is longer) in any other clinical study involving an investigational treatment or device.
-
Receiving strong Cytochrome3A4/5 (CYP3A4/5) inhibitors that have not been stopped for ≥5 days or a timeframe equivalent to 5 half-lives (whichever is longer), or strong CYP3A4/5 inducers that have not been stopped for ≥4 weeks or a timeframe equivalent to 5 half-lives (whichever is longer), before randomization.
-
Receiving anabolic steroids that have not been stopped for at least 4 weeks before randomization. Testosterone replacement therapy to treat hypogonadism is allowed; the testosterone dose and preparation must be stable for ≥12 weeks before randomization.
-
Known allergy, or other contraindication, to mitapivat or its excipients (microcrystalline cellulose, croscarmellose sodium, sodium stearyl fumarate, mannitol, magnesium stearate, and the Opadry filmcoat [hypromellose, titanium dioxide, lactose monohydrate triacetin, and FD&C Blue #2]).
-
Any medical, hematological, psychological, or behavioral condition(s) or prior or current therapy that, in the opinion of the Investigator, may confer an unacceptable risk to participating in the study and/or could confound the interpretation of the study data. Also excluded are:
- Participants who are institutionalized by regulatory or court order.
- Participants with any condition(s) that could create undue influence (including but not limited to incarceration, involuntary psychiatric confinement, and financial or familial affiliation with the Investigator or Sponsor).
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Mitapivat
Participants will receive oral mitapivat twice daily (BID), with dose determined by age and weight, for 48 weeks during the double blind (DB) period. Enrollment is conducted sequentially by age cohort, beginning with the oldest cohort. Cohort 1: 12 to <18 years Cohort 2: 6 to <12 years Cohort 3: 1 to <6 years Participants who complete the DB period may continue receiving mitapivat in the open label extension (OLE) period for up to 144 weeks. |
Tablets or Granules
Andre navne:
|
|
Placebo komparator: Placebo
Participants will receive oral placebo matching mitapivat, administered BID, with dosing based on age and weight, for 48 weeks during the DB period. Enrollment is conducted sequentially by age cohort, beginning with the oldest cohort. Cohort 1: 12 to <18 years Cohort 2: 6 to <12 years Cohort 3: 1 to <6 years Participants who complete the DB period may transition to receive mitapivat in the OLE period for up to 144 weeks. |
Tablets or Granules
Andre navne:
Tablets or Granules |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Participants Who Achieved Transfusion Reduction Response (TRR) Through Week 48
Tidsramme: Baseline, through Week 48
|
TRR is defined as ≥50 percent (%) reduction in transfused red blood cells (RBC) volume (normalized by weight) in any consecutive 12-week period through Week 48 compared with historical RBC transfusion volume (normalized by weight) and standardized to 12 weeks. |
Baseline, through Week 48
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Procentvis ændring i transfunderet RBC-volumen (normaliseret efter vægt) fra uge 13 til uge 48 sammenlignet med historisk transfusionsvolumen (normaliseret efter vægt) og standardiseret til 36 uger
Tidsramme: Baseline, uge 13 til uge 48
|
Baseline, uge 13 til uge 48
|
|
|
Ændring i antallet af transfusionsepisoider fra uge 13 til uge 48 sammenlignet med historisk antal transfusionsepisoider standardiseret til 36 uger
Tidsramme: Baseline, uge 13 til uge 48
|
Baseline, uge 13 til uge 48
|
|
|
Ændring fra baseline i serumjern ved uge 48
Tidsramme: Baseline, uge 48
|
Baseline, uge 48
|
|
|
Ændring fra baseline i total jernbindingskapacitet ved uge 48
Tidsramme: Baseline, uge 48
|
Baseline, uge 48
|
|
|
Ændring fra baseline i transferrin ved uge 48
Tidsramme: Baseline, uge 48
|
Baseline, uge 48
|
|
|
Ændring fra baseline i transferrinmætning ved uge 48
Tidsramme: Baseline, uge 48
|
Baseline, uge 48
|
|
|
Ændring fra baseline i serum ferritin-niveauer ved uge 48
Tidsramme: Baseline, uge 48
|
Baseline, uge 48
|
|
|
Kohorte 1: Ændring fra baseline i østradiol gennem uge 48
Tidsramme: Baseline, gennem uge 48
|
Baseline, gennem uge 48
|
|
|
Kohorte 1: Ændring fra baseline i estron gennem uge 48
Tidsramme: Baseline, gennem uge 48
|
Baseline, gennem uge 48
|
|
|
Kohorte 1: Ændring fra baseline i total testosteron gennem uge 48
Tidsramme: Baseline, gennem uge 48
|
Baseline, gennem uge 48
|
|
|
Kohorte 1: Ændring i frit testosteron fra baseline til uge 48
Tidsramme: Baseline, gennem uge 48
|
Baseline, gennem uge 48
|
|
|
Kohorte 1: Ændring fra udgangspunkt i luteiniserende hormon gennem uge 48
Tidsramme: Baseline, gennem uge 48
|
Baseline, gennem uge 48
|
|
|
Kohorte 1: Ændring fra baseline i seksuel modningsgrad med Tanner-stadie gennem uge 48
Tidsramme: Baseline, gennem uge 48
|
Baseline, gennem uge 48
|
|
|
Ændring fra baseline over tid i højde-for-alder Z-score, vægt-for-alder Z-score og Body Mass Index (BMI)-for-alder Z-score gennem uge 48
Tidsramme: Baseline, gennem uge 48
|
Baseline, gennem uge 48
|
|
|
Ændring fra baseline i knoglemineraltæthed (BMD) gennem uge 48
Tidsramme: Baseline, gennem uge 48
|
Baseline, gennem uge 48
|
|
|
Antal deltagere med behandlingsrelaterede bivirkninger (AEs) og alvorlige bivirkninger (SAEs)
Tidsramme: Fra første dosis af undersøgelsesmedicinen til undersøgelsens afslutning (op til uge 196)
|
Fra første dosis af undersøgelsesmedicinen til undersøgelsens afslutning (op til uge 196)
|
|
|
Plasmakoncentration af Mitapivat
Tidsramme: Før dosering, og på flere tidspunkter (op til 7 timer efter dosering) i uge 4
|
Før dosering, og på flere tidspunkter (op til 7 timer efter dosering) i uge 4
|
|
|
Areal under plasmakoncentrationstids-kurven fra tidspunkt nul til sidste kvantificerbare koncentration (AUC0-sidst) for Mitapivat
Tidsramme: Før dosis og på flere tidspunkter (op til 7 timer efter dosis) i uge 4
|
Før dosis og på flere tidspunkter (op til 7 timer efter dosis) i uge 4
|
|
|
Maksimal observeret plasmakoncentration (Cmax) af Mitapivat
Tidsramme: Prædosis, og på flere tidspunkter (op til 7 timer efter dosis) i uge 4
|
Prædosis, og på flere tidspunkter (op til 7 timer efter dosis) i uge 4
|
|
|
Tid til at nå den maksimale observerede plasmakoncentration (Tmax) for Mitapivat
Tidsramme: Før dosering og på flere tidspunkter (op til 7 timer efter dosering) i uge 4
|
Før dosering og på flere tidspunkter (op til 7 timer efter dosering) i uge 4
|
|
|
Kohorte 1: Procentdel af kvindelige deltagere med nyudviklede æggestokcyster gennem uge 48
Tidsramme: Baseline, gennem uge 48
|
Baseline, gennem uge 48
|
|
|
Percentage of Participants Who Achieved TRR2 From Week 13 to Week 24
Tidsramme: Baseline, Week 13 through Week 24
|
TRR2 is defined as ≥50% reduction in transfused RBC volume (normalized by weight) from week 13 to week 24 compared with historical RBC transfusion volume (normalized by weight) and standardized to 12 weeks. |
Baseline, Week 13 through Week 24
|
|
Percentage of Participants Who Achieved TRR3 From Week 25 to Week 36
Tidsramme: Baseline, Week 25 through Week 36
|
TRR3 is defined as ≥50% reduction in transfused RBC volume (normalized by weight) from week 25 to week 36 compared with historical RBC transfusion volume (Normalized by Weight) and standardized to 12 weeks. |
Baseline, Week 25 through Week 36
|
|
Percentage of Participants Who Achieved TRR4 From Week 37 to Week 48
Tidsramme: Baseline, Week 37 through Week 48
|
TRR4 is defined as ≥50% reduction in transfused RBC volume (normalized by weight) from week 37 to week 48 compared with historical RBC transfusion volume (normalized by weight) and standardized to 12 weeks. |
Baseline, Week 37 through Week 48
|
|
Percentage of Participants Who Achieved TRR5 From Week 25 to Week 48
Tidsramme: Baseline, Week 25 through Week 48
|
TRR5 is defined as ≥50% reduction in transfused RBC volume (normalized by weight) from week 25 to week 48 compared with historical RBC transfusion volume (normalized by weight) and standardized to 24 weeks. |
Baseline, Week 25 through Week 48
|
|
Percentage of Participants Who Achieved Transfused Independence Through Week 48
Tidsramme: Baseline, through Week 48
|
Transfusion independence is defined as transfusion-free for greater than or equal to 8 consecutive weeks through Week 48. |
Baseline, through Week 48
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- AG348-C-029
- 2025-524707-71-00 (Ctis)
- 2025 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .